Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials

Abstract

ObjectivesAn increased risk of tuberculosis (TB) has been reported in patients treated with TNF-α antagonists, an issue that has been highlighted in a WHO black box warning. This review aimed to assess the risk of TB in patients undergoing TNF-α antagonists treatment.MethodsA systematic literature search for randomised controlled trials (RCTs) was performed in MEDLINE, Embase and Cochrane library and studies selected for inclusion according to predefined criteria. ORs with 95% CIs were calculated using the random-effect model. Subgroup analyses considered the effects of drug type, disease and TB endemicity. The quality of evidence was assessed using the Grades of Recommendation, Assessment, Development and Evaluation (GRADE) approach.Results29 RCTs involving 11 879 patients were included (14 for infliximab, 9 for adalimumab, 2 for golimumab, 1 for etanercept and 3 for certolizumab pegol). Of 7912 patients allocated to TNF-α antagonists, 45 (0.57%) developed TB, while only 3 cases occurred in 3967 patients allocated to control groups, resulting in an OR of 1.94 (95% CI 1.10 to 3.44, p=0.02). Subgroup analyses indicated that patients of rheumatoid arthritis (RA) had a higher increased risk of TB when treated with TNF-α antagonists (OR 2.29 (1.09 to 4.78), p=0.03). The level of the evidence was recommended as ‘low’ by the GRADE system.ConclusionsFindings from our meta-analysis indicate that the risk of TB may be significantly increased in patients treated with TNF-α antagonists. However, further studies are needed to reveal the biological mechanism of the increased TB risk caused by TNF-α antagonists treatment.

Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: A retrospective cohort analysis

“…13 Cumulative TB incidence was higher among patients using belatacept, a fusion protein containing cytotoxic T-lymphocyte associated protein 4 and the Fc-fragment of IgG1. 10,14 Experimental studies suggest that lymphocyte costimulation is necessary for granuloma formation. 10,14 Experimental studies suggest that lymphocyte costimulation is necessary for granuloma formation.…”

“…2 Several studies focusing on clinical presentation and outcomes report that TB occurs primarily within the first year after KT, as a consequence of latent TB reactivation and/or donor-derived infection. 10 The aim of this study was to determine the influence of ISS on the incidence, timing, clinical presentation, diagnosis, treatment, and outcomes of TB after KT. To our knowledge, no studies have investigated the influence of ISS on TB incidence.…”

Miliary tuberculosis and herpes pharyngitis after a trip to a developing country: dangers of biologics

“…The risk of TB is significantly increased in those individuals on anti-TNF-α treatments 8. Anti-TNF-α therapy impairs the ability to form and maintain granulomas, increasing the risk of granulomatous diseases like TB 9.…”

Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study

“…Indeed, a substantially increased risk of TB in rheumatologic conditions managed with TNF‐targeted therapies has been demonstrated by several registries . A systematic meta‐analysis of randomized clinical trials also reported almost 2‐fold elevated risk of TB by anti‐TNF‐α agents . Available findings regarding TB risk led to development of guidelines/consensus reports that recommended implementation of screening and, if necessary, chemoprophylaxis in patients who were candidates for anti‐TNF‐α therapy …”